Thursday
February 13, 2025
6:31 AM ET
Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
Thursday
February 6, 2025
7:00 AM ET
Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025
Monday
January 13, 2025
7:00 AM ET
Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio
Wednesday
January 8, 2025
7:00 AM ET
FDA Accepts Agios’ Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia
Wednesday
December 18, 2024
7:00 AM ET
European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios’ Mitapivat in Sickle Cell Disease
Sunday
December 8, 2024
12:40 PM ET
Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat
Tuesday
November 5, 2024
9:05 AM ET
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition
Thursday
October 31, 2024
6:30 AM ET
Agios Reports Business Highlights and Third Quarter 2024 Financial Results
Wednesday
October 23, 2024
7:00 AM ET
Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease
Thursday
October 17, 2024
7:00 AM ET
Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024